N/A
N=7
Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Bottom Line
View on ClinicalTrials.gov: NCT05644730 ↗Enrolled (actual)
7
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Primary Safety Outcome — 1.4 Percentage of all glucose values
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Fusion closed loop glucose control system (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Ideal Medical Technologies
- Primary completion
- Apr 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Primary Safety Outcome |
1.4 | — |
| PRIMARY Primary Efficacy Outcome |
79.0 | — |
| SECONDARY Percent of All Glucose Values Within Glucose Range < 54 mg/dL |
— | — |
| SECONDARY Percent of All Glucose Values Within Glucose Range > 180 mg/dL |
19.6 | — |
| SECONDARY Percent of All Glucose Values Within Glucose Range > 250 mg/dL |
2.9 | — |
| SECONDARY Average Glucose Value in mg/dL |
148.4 | — |
| SECONDARY Percent Coefficient of Variation of Glucose |
21.3 | — |
| SECONDARY Weight in Kilograms |
88.2 | — |
| SECONDARY Body Mass Index |
31.0 | — |
| SECONDARY Total Daily Dose of Insulin in Units/Kilogram |
0.9 | — |
| SECONDARY Hemoglobin A1c Percentage Level |
8.5 | — |
| SECONDARY C-Peptide Level in ng/mL |
1.5 | — |
Summary
This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting.
The type 1 and type 2 diabetic subjects in this study will have their glucose controlled to a range of 100-140 mg/dL by a novel artificial intelligence based closed loop glucose control system for a period of 24 hours. The subjects will consume three standardized meals during the 24 hour study period.
Eligibility Criteria
Inclusion Criteria
- Are 18-70 years of age, inclusive.
- Can understand and sign an informed consent, communicate with the investigator, and understand and comply with the protocol requirements.
- Have had a diagnosis of type 1 or type 2 diabetes for a period of at least 1 year.
- Use insulin injections at home for glucose control and are on a stable insulin regimen without more than a 20% change in their total daily insulin dose during the previous 3 months. Their total daily insulin dose during the previous 3 months will be confirmed through a review of the subject's electronic health record, insulin prescriptions, and insulin pump settings (if applicable).
- Have a hemoglobin A1c (HbA1c) in the range of 7.0 - 10.0%.
- Have a hemoglobin in the normal range for sex:
- Females: 12-15.5 grams/dL.
- Males: 13.5-17.5 grams/dl.
- Have adequate venous access sites in upper extremities.
- Body weight between 40 - 150 kg.
Exclusion Criteria
- Have participated in an interventional medical, surgical, or pharmaceutical study within 30 days of screening.
- Have a known hypersensitivity to any of the components of study treatment.
- Have skin disease/injury at Dexcom G6 CGM insertion site(s) that would prevent insertion of the CGM.
- Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant.
- Have a medical condition that in the opinion of the investigator could affect study participation and/or personal well-being.
- Have a clinically significant history or presence of any of the following conditions:
- Hepatic failure or has alanine aminotransferase (ALT) greater than 3 times the upper limit of normal.
- Has an estimated glomerular filtration rate (GFR) <60 ml/min/1.73 m2 or End Stage Kidney Disease on renal replacement therapy.
- Type 2 diabetic subjects who have a C-peptide level less than 0.2 nmol/L (these subjects will be referred to their primary care doctor or endocrinologist for further work up).
- Have congestive heart failure of class 1 or greater on the New York Heart Association (NYHA) classification system.
- Have a history of seizures.
- Have a history of cerebrovascular accident.
- Have a history of ischemic heart disease.
- For female subjects of potential childbearing age (age 18 to 55) they will be excluded if:
- Pregnant.
- Refuse to agree to a pregnancy test at the time of enrollment.
- Have a positive urine pregnancy test at the time of enrollment.
- Have a positive COVID-19 test within 14 days of visit 3.
- Have any COVID-19 related symptoms in the 14-day period prior to visit 3.
- Have a known unprotected COVID-19 exposure in the 14-day period prior to visit 3.
Data sourced from ClinicalTrials.gov (NCT05644730). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.